

PRODUCT INFORMATION



EGFR Inhibitor

Item No. 15363

CAS Registry No.: 879127-07-8
Formal Name: N-[3-[[6-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-cyclopropanecarboxamide

Synonym: Epidermal Growth Factor Receptor Inhibitor, ErbB-1 Inhibitor, HER1 Inhibitor

MF: C₂₁H₁₈F₃N₅O
FW: 413.4


Purity: ≥98%

UV/Vis.: λ_{max}: 253, 302 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

EGFR inhibitor is supplied as a crystalline solid. A stock solution may be made by dissolving the EGFR inhibitor in the solvent of choice. EGFR inhibitor is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of EGFR inhibitor in these solvents is approximately 0.2, 20, and 25 mg/ml, respectively.

EGFR inhibitor is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, EGFR inhibitor should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. EGFR inhibitor has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

EGFR inhibitor is a cell permeable, 4,6-disubstituted pyrimidine compound that selectively inhibits the EGFR kinase with an IC₅₀ value of 21 nM *in vitro* and blocks receptor autophosphorylation in cells.¹ It can also inhibit the L858R and L861Q EGFR mutants (IC₅₀s = 63 and 4 nM, respectively) yet displays strong selectivity for EGFR against a panel of 55 recombinant kinases (IC₅₀s > 10 μM).¹ Whereas overactivity of EGFR tyrosine kinases has been associated with a number of cancers, inhibition of EGFR has been shown to induce apoptosis by downregulating antiapoptotic proteins such as survivin and upregulating proapoptotic proteins such as Bim.^{2,3}

References

1. Zhang, Q., Liu, Y., Gao, F., *et al.* Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. *J. Am. Chem. Soc.* **128(7)**, 2182-2183 (2006).
2. Ciardiello, F. and Tortora, G. EGFR antagonists in cancer treatment. *N. Engl. J. Med.* **358(11)**, 1160-1174 (2008).
3. Okamoto, K., Okamoto, I., Okamoto, W., *et al.* Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. *Cancer Res.* **70(24)**, 10402-10410 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/23/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM